

Neuland Laboratories Limited

Sanali Info Park, 'A' Block,
Ground Floor, 8-2-120/113
Road No. 2, Banjara Hills
Hyderabad - 500 034,
Telangana, India.

Tel: 040 30211600 / 23551081

Fax: 040 30211602

Email: neuland@neulandlabs.com

www.neulandlabs.com

April 8, 2017

To
BSE Limited
PhirozeJeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai - 400 001

To
The National Stock Exchange of India Ltd.
Exchange Plaza,
BandraKurla Complex, Bandra (E)
Mumbai - 400 001

Scrip Code: 524558

**Scrip Code: NEULANLAB
Series: EQ**

Dear Sirs,

We wish to inform you that the United States Food and Drug Administration (US FDA) inspected our Unit 1 manufacturing facility at Bonthapally, Hyderabad from 3rd to 7th of April 2017.

At the end of the inspection, there were 2 observations given under form 483. The two observations relate to a) procedures followed for the annual quality standards record evaluation and b) cleaning and maintenance of equipment at appropriate intervals during manufacturing campaign.

The Company has already initiated corrective and preventive actions for the observations and is confident of satisfying the FDA within the stipulated time.

This is for your information and records.

Yours faithfully,
For Neuland Laboratories Limited



Sarada Bhamidipati
Company Secretary